Title: Pfizer (NYSE:PFE) Discontinues Danuglipron Development After Safety Review in Study
Date: 2025-04-14 17:23
URL: https://finance.yahoo.com/news/pfizer-nyse-pfe-discontinues-danuglipron-172306284.html?.tsrc=rss

Oops, something went wrong
Tip: Try a valid symbol or a specific company name for relevant results
Oops, something went wrong
The Nasdaq briefly turned red as stocks' relief rally failed to hold in early afternoon trading
Americans are braced for the biggest unemployment rate jump since the pandemic, a New York Fed survey found
Stocks surge as Apple leads way higher after tech's tariff reprieve
Trump's temporary tech tariff respite adds to a growing sense that he has a willingness to listen and bend
Goldman CEO Solomon warns of 'markedly different operating environment' as dealmaking slows
Corporate earnings take center stage amid tariff turmoil: What to know this week
Trump has tariffs, taxes, and the debt ceiling on a collision course for this summer
Trump denies that there was a tariff “exception” for certain electronics announced Friday. (Bloomberg)
Tax day 2025 is coming up. Here’s what to know to file by the deadline.
Commentary: Put the P/E ratio in timeout for now
Market chaos signals 'sell America' trade as Trump tariff whipsaw threatens to upend the US economy's soft landing
Apple was on brink of crisis before tariff concession from Trump (Bloomberg)
Corporate earnings take center stage amid tariff turmoil: What to know this week
The best (and worst) time of year to buy a house
The Trump family is going all-in on crypto projects, from Bitcoin mining to stablecoins (Bloomberg)
How to invest in gold in 4 steps
Changing jobs can disrupt saving for retirement. Here's how to stay on track.
Trump exempts phones, computers, chips from ‘reciprocal’ tariffs (Bloomberg)
Meet Walmart heir Steuart Walton, the most powerful board member you’ve never heard of
The tariff uncertainty isn't getting any better in markets: Chart of the Week
'T-shirts could be the new eggs': Why Trump's chaotic tariff whipsaw is still a huge threat to inflation
Gold notches best week since 2020 amid 'shaken' investor confidence in US
The bond market just had one of its most volatile and unusual weeks in recent memory
Stocks capped a wild week with a surge higher, as the S&P 500 posted its biggest weekly gain since 2023
Stocks swung into rally mode in afternoon trading, with the major indexes all up over 1%. Bond yields pared bigger gains.
The major indexes whipsawed to end a volatile week. Treasury yields surged in signs of more instability in the bond market.
Consumer sentiment craters further as inflation expectations soar to highest since 1981
Dow, S&P 500, Nasdaq slide as China hits US with tariff hike, bank earnings roll in
JPMorgan's Dimon says economy is facing 'considerable turbulence'
Tariff uncertainty muddies — and refocuses — earnings season
China raises tariffs on US goods to 125% from the 84% planned in response to Trump's latest hike
China already knows Trump's breaking point in their burgeoning trade war, our columnist writes
How the bond market helped make Trump blink on tariffs
The Dow fell 1,000 points, and the S&P 500 and Nasdaq were crushed as stocks resumed a tariff-fueled sell-off
Trump's total tariff on China is actually 145%, the White House said, an amount higher than the 125% previously reported
Stocks hit session lows as focus turned to the US-China trade war. The Dow lost over 1,200 points, and the Nasdaq plunged 4.5%.
The Dow plummeted 900 points and the Nasdaq plunged over 3% as a tariff-fueled sell-off picked up speed again.
Stocks plummet as Wall Street's euphoria from Trump's tariff pause gets a reality check
Inflation unexpectedly tumbled in March, and core CPI rose at its slowest pace in four years.
The EU matched Trump's 90-day pause on tariffs to 'give negtiations a chance.' See our live updates.
The 'Trump put' makes an appearance
March's report could be last time investors see inflation easing. Here's what to expect.
Stocks wanted one thing from Trump after his shocking tariff announcement last week. They finally got it today.
Stocks staged a wild rally after Trump's tariff reversal. The Dow gained near 3,000 points and the S&P 500 had its best day since 2008.
Trump nodded to market turbulence as a factor in his 'reciprocal' tariff pause, saying investors were 'yippy' and 'afraid'
The Nasdaq was up 10%, aiming for its biggest gain since 2008, after Trump paused some tariffs. The Dow soared 2,500 points.
Trump unilaterally raises tariff rate on China to 125%, pauses 'reciprocal' tariffs on other countries
The major indexes rocketed higher after Trump announced a '90-day pause on tariffs for most countries.
Investors grapple with bond chaos as long-term yields soar following Trump's sweeping tariffs
Trump tries to reassure Americans as markets reel from tariff shocks
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Pfizerrecently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in its share price over the past week. This move was primarily due to safety concerns in clinical studies. Despite achieving key pharmacokinetic goals, the discovery of a potential drug-induced liver injury prompted Pfizer to reassess its strategy. This decision adds weight to the company's stock performance, contrasting with broader market trends, where major indexes experienced upward movement amidst tariff-related developments and positive gains in tech sectors. Pfizer's decision highlights the importance of rigorous safety evaluations in pharmaceutical developments.
We've discovered 3 warning signs for Pfizer (2 are significant!) that you should be aware of before investing here.
Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
The cessation of Danuglipron’s development could significantly influence Pfizer's revenue and earnings forecasts moving forward. By prioritizing rigorous safety measures, Pfizer may face setbacks in accelerating R&D productivity and the associated revenue streams. This shift may lead to a more conservative approach in pipeline-driven growth expectations and could delay anticipated financial impacts from new products, potentially further pressuring revenue forecasts already impacted by legislative changes. The development halt aligns with observed market volatility around Pfizer shares, shedding light on investor concerns regarding the company's future earning capabilities amidst evolving challenges in the pharmaceutical sector.
Over the past year, Pfizer's total return, including dividends, was a 10.14% decline, signaling underperformance relative to both the broader market and the US Pharmaceuticals industry, which experienced negative returns of 8.6%. During this period, the company's earnings showed considerable growth from a very low base, yet they have not matched market expectations overall. Notably, analysts have set a fair value price target of US$26.02, suggesting upside potential compared to the current share price of US$22.49. However, this assumes improvements in profit margins and financial performance that are not without risk given current operational challenges and headwinds from pricing reforms in Medicare.
Understand Pfizer's track record by examining our performance history report.
This article by Simply Wall St is general in nature.We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article includeNYSE:PFE.
Have feedback on this article? Concerned about the content?Get in touchwith us directly.Alternatively, emaileditorial-team@simplywallst.com
We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks on Jim Cramer’s radar. On Thursday, Mad Money host Jim Cramer cautioned viewers about what may lie ahead once the 90-day pause on new […]
The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.
↗️ Goldman Sachs (GS): The Wall Street bank posted better-than-expected results, boosted by a surge in equities trading in the first quarter, which ended just before President Trump's sweeping tariffs disrupted markets.
Pfizer (PFE) announced Monday that it is ending development of its daily weight-loss pill following a liver injury to a patient participating in a trial.
Anthony Scaramucci, the former White House communications director turned fierce Trump critic, says President Donald Trump’s chaotic trade policies are wreaking havoc on the markets, and the damage isn’t just economic. ‘Trump Is the Virus,’ Says Former Aide “This is COVID-like selling, but now Trump is the virus and there is no cure. Except the 25th Amendment,” Scaramucci posted on X on Monday. The post came as stocks reeled from Trump’s aggressive new tariffs, which were announced as part of hi
Jeep and Chrysler parent Stellantis will face greater headwinds from tariffs than its counterparts in Detroit, UBS analysts said.
Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial.
Argentina's grain industry welcomed an exchange-rate overhaul on Monday, though the new measures will likely not translate into immediate sales as the harvest remains behind schedule, experts said.  Late on Friday, Argentina's central bank loosened foreign-exchange controls, a long-awaited measure twinned with billions of dollars to be disbursed by development banks including the International Monetary Fund.  Lifting of the controls is also meant to speed up agricultural sales, a prime source of cash from abroad.
Crypto exchanges and wallet apps must meet EU's MiCA licensing rules to advertise in Google's platforms in 27 countries.
Retiring on a fixed income can seem daunting, but with some planning and commitment to a frugal lifestyle, it's possible to retire comfortably on $2,000 a month. This takes discipline but ultimately...
Tip: Try a valid symbol or a specific company name for relevant results
Sign in to access your portfolio
Try again.